Editing Sorin Spitt (section)

== Snubable Enterprise ==

Spitt examined newly manufactured clones after they were removed from incubation. He treated complications that developed after accelerated maturation and examined clones whose physical development appeared abnormal. He also conducted experimental procedures on living clones and performed post-mortem examinations on failed specimens. In 2005, Spitt established through repeated examinations that Snubable-produced clones were infertile.

The [[Bucharest Butchers]] assumed direct control over Snubable's protection and transport structure on 7 April 2007.<ref name="snubable-control"/> On the same date, Spitt was appointed the first Head of Clone Medicine. He remained in the office until 6 May 2025. After taking the position, he introduced a rule requiring the most medically unstable clones to wear no tie so that staff could identify them immediately. He also required every failed clone to undergo a post-mortem examination before disposal.

These examinations led Spitt to identify multi-organ instability as a recurring cause of failed development. He found that the most unstable clones could complete visible physical maturation while individual organs developed at different rates. The resulting bodies were unable to maintain stable organ function after leaving incubation. Spitt used these findings when assessing newly manufactured clones.

Snubable classified its manufactured clones as Jester, Standard or Elite according to their physical stability and cognitive performance.<ref name="clone-production"/> Spitt formalized the medical criteria used during these assessments. His examinations covered organ stability and neurological function before a clone received its final classification. The no-tie rule remained an additional marker for clones considered especially unstable.

The [[R-Series]] entered production in September 2011 using [[Rasmus Rogganoid]] as its genetic source instead of the main Alexandru-derived production line.<ref name="r-series"/> Spitt examined R-Series clones and compared their development with the main Snubable clone population. His work concentrated on differences in physical stability after accelerated maturation.

In 2017, Snubable selected Elite clones for armed deployment during [[Aktion Shrankenhaus]].<ref name="aktion"/> Spitt developed the medical screening used to determine whether individual clones were physically stable enough for deployment. Clones that failed his screening remained excluded from the armed units.

Spitt became lead physician for [[Project Umbrar]] when Snubable began experiments using human biological material and tissue from the [[Borvă]] specimen UB-01 in 2021. The resulting Umbrars repeatedly suffered tissue instability and poor survival.<ref name="umbrar"/> Spitt concluded that the failures were not caused by a single defect. Tissue development became unstable after maturation, metabolic regulation deteriorated and neurological development failed to remain integrated with the rest of the body. Snubable ended the Umbrar program on 3 November 2022.<ref name="umbrar"/>